Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.

Leroux-Roels, Isabel; Leroux-Roels, Geert; Shukarev, Georgi; Schuitemaker, Hanneke; Cahill, Conor; de Rooij, Richard; Struijs, Martin; van Zeeburg, Hester; Jacquet, Jeanne-Marie

Leroux-Roels, Isabel; Leroux-Roels, Geert; Shukarev, Georgi; Schuitemaker, Hanneke; Cahill, Conor; de Rooij, Richard; Struijs, Martin; van Zeeburg, Hester; Jacquet, Jeanne-Marie.

Afiliação

Leroux-Roels I; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
Leroux-Roels G; Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
Shukarev G; Janssen Vaccines AG, Bern, Switzerland.
Schuitemaker H; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
Cahill C; Takeda Pharmaceuticals, Zurich, Switzerland.
de Rooij R; Takeda Pharmaceuticals, Zurich, Switzerland.
Struijs M; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
van Zeeburg H; DCPrime BV, Leiden the Netherlands.
Jacquet JM; Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Hum Vaccin Immunother ; 17(5): 1366-1373, 2021 05 04.

Article em En | MEDLINE | ID: mdl-33175637

Assuntos

Poliomielite; Poliovirus; Adulto; Anticorpos Antivirais; Bélgica; Linhagem Celular; Humanos; Imunogenicidade da Vacina; Vacina Antipólio de Vírus Inativado; Vacina Antipólio Oral

Palavras-chave

IPV; Inactivated; PER.C6; Sabin; poliovirus; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Poliomielite / Poliovirus Tipo de estudo: Clinical_trials Limite: Adult / Humans País como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google